TY - JOUR
T1 - Improved survival after allogeneic transplantation for acute lymphoblastic leukemia in adults
T2 - a Danish population-based study
AU - Gjærde, Lars Klingen
AU - Rank, Cecilie Utke
AU - Andersen, Mette Klarskov
AU - Jakobsen, Lasse Hjort
AU - Sengeløv, Henrik
AU - Olesen, Gitte
AU - Kornblit, Brian
AU - Marquart, Hanne
AU - Friis, Lone Smidstrup
AU - Petersen, Søren Lykke
AU - Andersen, Niels Smedegaard
AU - Nielsen, Ove Juul
AU - Toft, Nina
AU - Schjødt, Ida
PY - 2022/2
Y1 - 2022/2
N2 - We investigated trends of survival in a population-based cohort study of all 181 adults who received HCT for ALL in Denmark between 2000-2019. Patients had a median (min-max) age of 36 (18-74) years at HCT and were followed for a median of eight years. Overall survival (OS) improved over time with an estimated 2-year OS of 49% (CI 27-66%) in year 2000 versus 77% (CI 59-88%) in year 2019. More patients achieved cure over time (OR for cure per year 1.07, CI 1.00-1.15), while the rate of death in non-cured patients remained stable (HR of excess mortality per year 0.99, CI 0.93-1.06). Relapse decreased over time (HR 0.92 per year, CI 0.87-0.98), whereas non-relapse mortality did not change notably (HR 0.98 per year, CI 0.93-1.04). In conclusion, survival after HCT in adults with ALL has improved over the past two decades, primarily due to more patients achieving cure.
AB - We investigated trends of survival in a population-based cohort study of all 181 adults who received HCT for ALL in Denmark between 2000-2019. Patients had a median (min-max) age of 36 (18-74) years at HCT and were followed for a median of eight years. Overall survival (OS) improved over time with an estimated 2-year OS of 49% (CI 27-66%) in year 2000 versus 77% (CI 59-88%) in year 2019. More patients achieved cure over time (OR for cure per year 1.07, CI 1.00-1.15), while the rate of death in non-cured patients remained stable (HR of excess mortality per year 0.99, CI 0.93-1.06). Relapse decreased over time (HR 0.92 per year, CI 0.87-0.98), whereas non-relapse mortality did not change notably (HR 0.98 per year, CI 0.93-1.04). In conclusion, survival after HCT in adults with ALL has improved over the past two decades, primarily due to more patients achieving cure.
KW - acute lymphoblastic leukemia
KW - ALL
KW - allogeneic hematopoietic stem cell transplantation
KW - Allogeneic transplantation
KW - survival
UR - http://www.scopus.com/inward/record.url?scp=85117457557&partnerID=8YFLogxK
U2 - 10.1080/10428194.2021.1992620
DO - 10.1080/10428194.2021.1992620
M3 - Journal article
C2 - 34672245
SN - 1042-8194
VL - 63
SP - 416
EP - 425
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 2
ER -